Holen Sie sich die Stockscreener-App
528.68
0.98%
-5.24
Vorhandelsmarkt:
528.11
-0.57
-0.11%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IDXX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$533.92
Offen:
$531.805
24-Stunden-Volumen:
600.85K
Relative Volume:
1.12
Marktkapitalisierung:
$41.70B
Einnahmen:
$4.45B
Nettoeinkommen (Verlust:
$1.10B
KGV:
38.90
EPS:
13.591
Netto-Cashflow:
$1.06B
1W Leistung:
-8.73%
1M Leistung:
-7.90%
6M Leistung:
-24.63%
1J Leistung:
+3.84%
1-Tages-Spanne:
$523.38
$533.39
1-Wochen-Bereich:
$523.38
$585.12
52-Wochen-Spanne:
$496.61
$769.98
Idexx Laboratories Inc Stock (IDXX) Company Profile
Firmenname
Idexx Laboratories Inc
Sektor
Branche
Telefon
(207) 556-0300
Adresse
ONE IDEXX DRIVE, WESTBROOK, ME
Compare IDXX vs TMO, DHR, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
528.68 | 42.12B | 4.45B | 1.10B | 1.06B | 13.59 |
TMO
Thermo Fisher Scientific Inc
|
446.03 | 170.69B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
165.99 | 117.67B | 24.78B | 3.68B | 5.29B | 5.1743 |
WAT
Waters Corp
|
334.93 | 34.57B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
112.74 | 31.91B | 7.07B | 1.29B | 993.00M | 4.5355 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Citigroup | Neutral |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-31 | Hochstufung | Stifel | Hold → Buy |
| 2025-10-01 | Eingeleitet | UBS | Neutral |
| 2025-08-05 | Bestätigt | BTIG Research | Buy |
| 2025-07-01 | Eingeleitet | Jefferies | Buy |
| 2024-12-02 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | BTIG Research | Buy |
| 2024-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-12-07 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2023-12-04 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2023-08-02 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-07-25 | Herabstufung | Stifel | Buy → Hold |
| 2022-07-21 | Hochstufung | Goldman | Neutral → Buy |
| 2022-07-12 | Eingeleitet | Piper Sandler | Overweight |
| 2022-05-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-02-08 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-11-18 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-17 | Eingeleitet | Barclays | Overweight |
| 2019-09-09 | Eingeleitet | Goldman | Neutral |
| 2019-05-23 | Eingeleitet | Guggenheim | Buy |
| 2018-11-02 | Bestätigt | BofA/Merrill | Buy |
| 2018-05-07 | Bestätigt | Stifel | Buy |
| 2018-01-16 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-08-23 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-07-28 | Hochstufung | CL King | Neutral → Buy |
| 2017-02-03 | Herabstufung | Feltl & Co. | Hold → Sell |
| 2016-09-29 | Fortgesetzt | BofA/Merrill | Neutral |
| 2016-08-16 | Bestätigt | Stifel | Buy |
| 2016-08-03 | Hochstufung | Northcoast | Sell → Neutral |
| 2016-07-20 | Bestätigt | Canaccord Genuity | Buy |
| 2016-04-19 | Bestätigt | Canaccord Genuity | Buy |
| 2016-04-01 | Eingeleitet | CL King | Neutral |
| 2016-03-21 | Bestätigt | Stifel | Buy |
| 2016-02-04 | Eingeleitet | Credit Suisse | Outperform |
| 2015-10-29 | Bestätigt | Stifel | Buy |
| 2015-08-28 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2015-08-13 | Bestätigt | Stifel | Buy |
| 2015-07-23 | Bestätigt | Canaccord Genuity | Buy |
Alle ansehen
Idexx Laboratories Inc Aktie (IDXX) Neueste Nachrichten
IDEXX Laboratories, Inc. Stock 12‑Month Price Target Cut to $714.36, Implies 35% Upside - TradingView
IDEXX Laboratories, Inc. Stock 12‑Month Price Target Cut to $721.5, Implies 35% Upside - TradingView
IDEXX Laboratories Inc (IDXX) Stock Down 4.7% -- Now Undervalued? GF Score: 98/100 - GuruFocus
IDEXX Laboratories stock (US45167R1041): Shares fall 5% despite beating earnings estimates - AD HOC NEWS
IDEXX Laboratories Inc (IDXX) Shares Fall 5.0% -- What GF Score of 99 Tells Investors - GuruFocus
IDEXX (IDXX) director’s RSUs vest into 257 shares, holdings updated - Stock Titan
IDEXX (IDXX) director Szostak adds 257 shares as RSUs vest into stock - Stock Titan
IDEXX (IDXX) director Karen Peacock converts 101 RSUs into 102-share holding - Stock Titan
Director at IDEXX Laboratories (IDXX) gains 339 shares from RSU vesting - Stock Titan
IDEXX Laboratories (NASDAQ: IDXX) director gains 257 shares from RSU vesting - Stock Titan
Director Hooley of IDEXX (NASDAQ: IDXX) gains 158 common shares via RSU vesting - Stock Titan
IDEXX Laboratories Inc. stock underperforms Monday when compared to competitors - MarketWatch
BofA Sees Slower InVue Installations as Headwind for IDEXX Laboratories, Inc. (IDXX) - Insider Monkey
IDEXX Laboratories Drops 5.8% Amid Sector-Wide Selling - AlphaStreet
What you need to know ahead of IDEXX Laboratories' earnings release - MSN
IDEXX Laboratories stock (US45168D1046): Mixed price moves amid strong earnings and valuation debate - AD HOC NEWS
IDEXX Laboratories Inc. stock underperforms Friday when compared to competitors - MarketWatch
Here’s Why IDEXX Laboratories Stock Could Deliver Around 11% Annual Returns Despite a 15% YTD Pullback - TIKR.com
IDEXX Laboratories Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Analyst Estimates: Here's What Brokers Think Of IDEXX Laboratories, Inc. (NASDAQ:IDXX) After Its First-Quarter Report - Yahoo Finance
Companion Animal Diagnostics Market Valued at USD 7.6 Billion - openPR.com
Jefferies Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating, Cuts Target Price to $729 - Moomoo
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
Stifel Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating, Maintains Target Price $675 - 富途牛牛
Morgan Stanley Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating, Maintains Target Price $805 - Moomoo
IDEXX Laboratories Q1 2026 earnings preview - MSN
Transcript: IDEXX Laboratories Q1 2026 Earnings Conference Call - Sahm
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q1 2026 Earnings Call Transcript - Insider Monkey
Jefferies Adjusts Price Target on IDEXX Laboratories to $792 From $785 - marketscreener.com
IDEXX Laboratories Lifts Guidance on Robust Q1 - TipRanks
IDEXX Laboratories Inc | 10-Q: Q1 2026 Earnings Report - Moomoo
BofA cuts Idexx Laboratories stock price target on macro concerns By Investing.com - Investing.com South Africa
IDEXX (NASDAQ: IDXX) lifts Q1 profit and ramps up buybacks - Stock Titan
BofA cuts Idexx Laboratories stock price target on macro concerns - Investing.com
BofA Securities Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Cuts Target Price to $660 - 富途牛牛
Idexx Earnings: Strong Quarterly Results Lead to a More Optimistic Outlook From Management - Morningstar
IDEXX Laboratories Q1 Earnings Call Highlights - Yahoo Finance
William Blair Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating - 富途牛牛
IDEXX Laboratories, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:IDXX) 2026-05-05 - Seeking Alpha
IDEXX Laboratories, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
IDEXX Q1 2026 slides: raised guidance on strong diagnostic growth - Investing.com
Earnings call transcript: IDEXX Labs exceeds Q1 2026 forecasts, stock rises - Investing.com Nigeria
IDEXX Stock Up on Q1 Earnings & Revenue Beat, Margins Rise, '26 View Up - Yahoo Finance
Earnings call transcript: IDEXX Labs exceeds Q1 2026 forecasts, stock rises By Investing.com - Investing.com South Africa
Idexx Laboratories Raises Guidance On Higher Clinical Visits, Diagnostic Frequency - Benzinga
IDEXX beats expectations on Q1 results, raises 2026 outlook - Mainebiz
Is It Too Late To Consider IDEXX Laboratories (IDXX) After Its 18.5% One-Year Rally? - Yahoo Finance
IDEXX Laboratories Releases Q1 2026 Financial Results - AlphaStreet
IDEXX Laboratories Q1 Comparable Earnings, Revenue Rise - marketscreener.com
Q1 2026 IDEXX Laboratories Inc Earnings Call Transcript - GuruFocus
Research Alert: Idexx Posts Solid Q1 Fueled By Innovation And Strong Cag Group Performance - Moomoo
Finanzdaten der Idexx Laboratories Inc-Aktie (IDXX)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):